The goal of the Centralized Histopathology Laboratory (CHPL) is to provide histologic services to investigators at M.D. Anderson Cancer Center. The CHPL supplies technical support and consultation, develops or applies appropriate techniques, and maintains the consistency and high quality needed to perform these techniques. The CHPL is currently located in the Department of Pathology in 375 feet/2. Because of the increasing emphasis on in vivo systems in cancer biology and developmental biology, the number of laboratories using tissue specimens, transgenic mice, and gene-knockout technologies has increased dramatically. To provide efficient histology services to the institution, the CHPL will be expanded, and a second 370- feet/2 laboratory will be located in the R.E. """"""""Bob"""""""" Smith Research Building. The well-equipped and well-staffed CHPL processes fixed and frozen specimens for routine histologic analysis, immunohistochemical in situ hybridization (colorimetric procedures), and special staining for tissue sections and cells. The CHPL (both sites) is directed by Dr. Isaiah J. Fidler, and is accessible to all faculty, at M.D. Anderson Cancer Center, will preference given to investigators with peer-reviewed grants. Among the services provided are rapid preparation of high-quality standard histologic sections; application of special technologies as the need arises for selected projects, including preparation of frozen sections and histochemical, immunohistochemical, and tissue sections for in situ hybridization analysis; consultation with investigators to tailor technology to their special needs; and interpretation of histologic data. To access the CHPL, investigators make a formal application. After approval by the Director, the histotechnologist meets with the investigators to determine special needs of the study and the technical staff provides the histopathological services. The services are prioritized and coordinated to provide timely service. The development of new technologies that require additional equipment or special supplies has been funded by M.D. for specialized procedures such as in situ hybridization and 500 specially stained slides yearly. The increase in studies of transgenic mice and gene knockout mice will significantly increase the CHPL's workload, especially for special preparations such as serial sections of whole-embryos mounts. The CHPL is an essential component of the M.D. Anderson centralized research facilities that require histologic analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-24S3
Application #
6300101
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
24
Fiscal Year
2000
Total Cost
$332,337
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications